-

Covalon Announces Conference Call to Discuss First Quarter Financial Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will be releasing its Fiscal 2020 First Quarter financial results on Monday, March 2nd, 2020, after markets close. A conference call to discuss the financial results will be held Tuesday, March 3rd, 2020 at 9:00am EST. To participate in the conference call, please dial:

Local/International: (833) 299-8117
North American Toll-Free: (647) 689-4535
Conference ID Code: 1181198

A recording of the call will be available by calling (855) 859-2056 or (404) 537-3406 and entering the conference ID code 1181198 from Tuesday, March 3rd, 2020, at 12:00pm EST to Tuesday, March 17th, at 11:59pm EST. A recording of the call will also be available on www.covalon.com on the Investor page under Event Calendar.

Copies of Covalon’s financial statements and MD&A can be obtained on SEDAR at www.sedar.com, as well as the Investor Relations tab of the Company’s website at www.covalon.com.

About Covalon

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Contacts

Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

Covalon Technologies Ltd.

TSX VENTURE:COV
Details
Headquarters: Mississauga, Canada
CEO: Brent Ashton
Employees: 80
Organization: PUB

Release Versions

Contacts

Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

Social Media Profiles
More News From Covalon Technologies Ltd.

Covalon Reports Highest Revenue Quarter of Fiscal Year 2025, Delivers Third Consecutive Year of Revenue Growth

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 fourth quarter and full 2025 fiscal year results for the period ended September 30, 2025, along with a number of important recent achievements and highlights. Brent Ashton, Covalon’s Chief Executive Officer, commented, “Covalon has made significant progress as a company to close out our fiscal year 2025...

Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q4 and year end Fiscal 2025 financial results on Thursday, December 11, 2025, before markets open. A conference call and webcast to discuss the financial results will be held on Thursday, December 11, 2025, at 8:30am ET. To view, listen to, and participate in the live webcast, please follow the link below: https://eve...

Covalon Technologies Ltd. Announces Payment of First Ever Dividend, Marking a Milestone in Financial Strength

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the payment on November 18, 2025 of its first ever dividend – a special cash dividend of C$0.15 per common share – reflecting the Company’s strong financial performance and continued success in accelerating the adoption of its unique, patented, life-saving and life-improving medical technologies. This special dividend...
Back to Newsroom